Randomised Controlled Phase-2 Trial to Determine the Efficacy of Adoptive Immunotherapy With NK Cells in High-risk AML

Inclusion Criteria: * Newly diagnosed AML other than acute promyelocytic leukemia (APL) according to WHO criteria * In AML defined by cytogenetic aberrations the proportion of blasts may be \<20% * Age ≥60 years * Clinical performance corresponding to ECOG score 0-2 * High-risk karyotype * \<5% myeloblasts in bone marrow ≥21 days after beginning of most recent chemotherapy * maximal two preceding chemotherapy cycles * Potentially available haploidentical family donor (child/ sibling), willing and fit for NK cell donation Exclusion Criteria: * AML with favorable or intermediate risk cytogenetic features * Persistent aplasia following preceding chemotherapy * Relapsed or refractory AML * Known pre-existing autoimmune diseases * Any severe concomitant condition which makes it undesirable for the patient to participate in the study * Any condition which could jeorpadize compliance of the protocol * Participation in another clinical trial during or within 4 weeks before study entry